MS patients 'need better access to drugs'

Published Monday, 29 April 2013

Ten thousand people across the UK took part in the survey. (Getty)

Two of the most effective disease-modifying treatments (DMTs) are Tysabri and Fingolimod.

The licensed medicines can reduce the frequency and severity of MS attacks, and in some cases can slow the progression of disability.

Just 31% of people eligible for Tysabri are currently receiving it in Northern Ireland.

Based on NICE (National Institute for Health and Care Excellence) estimates, 16% of people with relapsing remitting MS in the region may be eligible for Fingolimod, the report by the MS Society also revealed.

It is an oral tablet which can reduce relapses by up to 60%.

In Northern Ireland, around one in every 500 people live with the disabling neurological condition.

The region has one of the highest rates of multiple sclerosis in the world.

Tom Mallon, Head of the MS Society in Northern Ireland, said: "These findings worryingly suggest that the likelihood of someone receiving a life changing treatment is often based on luck - like where they live or how helpful their healthcare professional is - rather than their genuine clinical need."

Originally posted here:
MS patients 'need better access to drugs'